Report from DIA-TOPRA Adaptive Pathways Workshop:
EU Adaptive Pathways: Ultimate Success Will Depend on Industry-Payer Communication
This white paper is part of DIA’s White Paper Library
Timely authorization of products expected to cover unmet or high-impact medical needs is vital to support innovation and to improve patient access. The introduction of adaptive pathways is challenging but initiatives such as the EMA adaptive licensing project and recognition of the issues around HTA approval for conditionally-approved products in the EU are helping shape the regulatory framework. The DIA-TOPRA Adaptive Pathways Workshop, June 2015 in Brussels, Belgium, considered how the regulatory hurdles to bringing such products to market could be overcome in order to improve patient access to vital new treatments.
Download Now!
INTERESTED IN PUBLISHING?
For more information on publishing your White Paper with DIA, including schedule and pricing, please contact Heej Ko at [email protected].
For more information on publishing your White Paper with DIA, including schedule and pricing, please contact Heej Ko at [email protected].